The man behind ‘value based pricing’ saw pharma distorting his message — and walked away

Stat News

13 May 2022 - When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave — it represented the “overall value this treatment brings to patients, caregivers and society” — came right out of Mick Kolassa’s playbook.

For many years, Kolassa was the man drug companies turned to when they wanted advice on how to price a drug.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder